nodes	percent_of_prediction	percent_of_DWPC	metapath
Repaglinide—SLCO1B1—Methotrexate—lymphatic system cancer	0.147	0.292	CbGbCtD
Repaglinide—CYP3A4—Cytarabine—lymphatic system cancer	0.0878	0.174	CbGbCtD
Repaglinide—CYP3A4—Teniposide—lymphatic system cancer	0.0865	0.172	CbGbCtD
Repaglinide—ALB—Methotrexate—lymphatic system cancer	0.0804	0.16	CbGbCtD
Repaglinide—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0605	0.12	CbGbCtD
Repaglinide—CYP3A4—Vincristine—lymphatic system cancer	0.0416	0.0827	CbGbCtD
Repaglinide—PPARG—Etoposide—Teniposide—lymphatic system cancer	0.0194	1	CbGdCrCtD
Repaglinide—Ischaemia—Mitoxantrone—lymphatic system cancer	0.0123	0.0257	CcSEcCtD
Repaglinide—Haemolytic anaemia—Mechlorethamine—lymphatic system cancer	0.00933	0.0195	CcSEcCtD
Repaglinide—Hepatic function abnormal—Teniposide—lymphatic system cancer	0.0071	0.0149	CcSEcCtD
Repaglinide—Haemolytic anaemia—Teniposide—lymphatic system cancer	0.00688	0.0144	CcSEcCtD
Repaglinide—Electrocardiogram abnormal—Mitoxantrone—lymphatic system cancer	0.00682	0.0143	CcSEcCtD
Repaglinide—Jaundice—Mechlorethamine—lymphatic system cancer	0.00632	0.0133	CcSEcCtD
Repaglinide—Cardiac failure congestive—Fludarabine—lymphatic system cancer	0.00602	0.0126	CcSEcCtD
Repaglinide—Visual disturbance—Fludarabine—lymphatic system cancer	0.00576	0.0121	CcSEcCtD
Repaglinide—Myocardial ischaemia—Mitoxantrone—lymphatic system cancer	0.00556	0.0117	CcSEcCtD
Repaglinide—Erythema multiforme—Mechlorethamine—lymphatic system cancer	0.00551	0.0115	CcSEcCtD
Repaglinide—Alopecia—Mechlorethamine—lymphatic system cancer	0.00515	0.0108	CcSEcCtD
Repaglinide—Hepatic enzyme increased—Mitoxantrone—lymphatic system cancer	0.00473	0.00991	CcSEcCtD
Repaglinide—Angina pectoris—Fludarabine—lymphatic system cancer	0.00459	0.00963	CcSEcCtD
Repaglinide—Leukopenia—Mechlorethamine—lymphatic system cancer	0.00454	0.00951	CcSEcCtD
Repaglinide—Bronchitis—Fludarabine—lymphatic system cancer	0.00453	0.0095	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.00429	0.00899	CcSEcCtD
Repaglinide—Hyperglycaemia—Fludarabine—lymphatic system cancer	0.00425	0.00892	CcSEcCtD
Repaglinide—Stevens-Johnson syndrome—Fludarabine—lymphatic system cancer	0.00417	0.00874	CcSEcCtD
Repaglinide—Acute coronary syndrome—Fludarabine—lymphatic system cancer	0.00414	0.00869	CcSEcCtD
Repaglinide—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.00414	0.00867	CcSEcCtD
Repaglinide—Myocardial infarction—Fludarabine—lymphatic system cancer	0.00412	0.00864	CcSEcCtD
Repaglinide—Urinary tract infection—Fludarabine—lymphatic system cancer	0.00409	0.00857	CcSEcCtD
Repaglinide—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.00405	0.00849	CcSEcCtD
Repaglinide—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00402	0.00843	CcSEcCtD
Repaglinide—Sinusitis—Fludarabine—lymphatic system cancer	0.00394	0.00827	CcSEcCtD
Repaglinide—Arrhythmia—Teniposide—lymphatic system cancer	0.00384	0.00804	CcSEcCtD
Repaglinide—Alopecia—Teniposide—lymphatic system cancer	0.00379	0.00795	CcSEcCtD
Repaglinide—Visual impairment—Fludarabine—lymphatic system cancer	0.00364	0.00762	CcSEcCtD
Repaglinide—Cardiac failure congestive—Mitoxantrone—lymphatic system cancer	0.00358	0.0075	CcSEcCtD
Repaglinide—Erythema multiforme—Fludarabine—lymphatic system cancer	0.00357	0.00748	CcSEcCtD
Repaglinide—Arrhythmia—Fludarabine—lymphatic system cancer	0.00337	0.00707	CcSEcCtD
Repaglinide—Anaphylactoid reaction—Mitoxantrone—lymphatic system cancer	0.00335	0.00703	CcSEcCtD
Repaglinide—Leukopenia—Teniposide—lymphatic system cancer	0.00335	0.00701	CcSEcCtD
Repaglinide—Alopecia—Fludarabine—lymphatic system cancer	0.00334	0.00699	CcSEcCtD
Repaglinide—Malnutrition—Fludarabine—lymphatic system cancer	0.00329	0.00689	CcSEcCtD
Repaglinide—Hypertension—Teniposide—lymphatic system cancer	0.00323	0.00676	CcSEcCtD
Repaglinide—Chest pain—Teniposide—lymphatic system cancer	0.00318	0.00667	CcSEcCtD
Repaglinide—Oedema—Teniposide—lymphatic system cancer	0.00305	0.00639	CcSEcCtD
Repaglinide—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00305	0.00639	CcSEcCtD
Repaglinide—Acute coronary syndrome—Bleomycin—lymphatic system cancer	0.00304	0.00637	CcSEcCtD
Repaglinide—Myocardial infarction—Bleomycin—lymphatic system cancer	0.00302	0.00633	CcSEcCtD
Repaglinide—Thrombocytopenia—Teniposide—lymphatic system cancer	0.00299	0.00626	CcSEcCtD
Repaglinide—Leukopenia—Fludarabine—lymphatic system cancer	0.00294	0.00616	CcSEcCtD
Repaglinide—Pruritus—Mechlorethamine—lymphatic system cancer	0.00293	0.00614	CcSEcCtD
Repaglinide—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00283	0.00593	CcSEcCtD
Repaglinide—Arthralgia—Fludarabine—lymphatic system cancer	0.0028	0.00586	CcSEcCtD
Repaglinide—Hyperglycaemia—Carmustine—lymphatic system cancer	0.00272	0.00571	CcSEcCtD
Repaglinide—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00268	0.00562	CcSEcCtD
Repaglinide—Oedema—Fludarabine—lymphatic system cancer	0.00268	0.00562	CcSEcCtD
Repaglinide—Vomiting—Mechlorethamine—lymphatic system cancer	0.00263	0.00552	CcSEcCtD
Repaglinide—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.00263	0.0055	CcSEcCtD
Repaglinide—Urinary tract infection—Carmustine—lymphatic system cancer	0.00262	0.00548	CcSEcCtD
Repaglinide—Rash—Mechlorethamine—lymphatic system cancer	0.00261	0.00547	CcSEcCtD
Repaglinide—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00261	0.00546	CcSEcCtD
Repaglinide—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.00253	0.00531	CcSEcCtD
Repaglinide—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	0.00253	0.0053	CcSEcCtD
Repaglinide—Myocardial infarction—Vincristine—lymphatic system cancer	0.00252	0.00528	CcSEcCtD
Repaglinide—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00249	0.00523	CcSEcCtD
Repaglinide—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.00247	0.00517	CcSEcCtD
Repaglinide—Nausea—Mechlorethamine—lymphatic system cancer	0.00246	0.00515	CcSEcCtD
Repaglinide—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.00245	0.00514	CcSEcCtD
Repaglinide—Alopecia—Bleomycin—lymphatic system cancer	0.00245	0.00513	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00244	0.00512	CcSEcCtD
Repaglinide—Jaundice—Mitoxantrone—lymphatic system cancer	0.00244	0.00511	CcSEcCtD
Repaglinide—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00243	0.0051	CcSEcCtD
Repaglinide—Urticaria—Teniposide—lymphatic system cancer	0.00242	0.00508	CcSEcCtD
Repaglinide—Abdominal pain—Teniposide—lymphatic system cancer	0.00241	0.00506	CcSEcCtD
Repaglinide—Erythema—Bleomycin—lymphatic system cancer	0.00241	0.00505	CcSEcCtD
Repaglinide—Paraesthesia—Fludarabine—lymphatic system cancer	0.00241	0.00505	CcSEcCtD
Repaglinide—Oedema peripheral—Carmustine—lymphatic system cancer	0.00238	0.00499	CcSEcCtD
Repaglinide—Dyspepsia—Fludarabine—lymphatic system cancer	0.00236	0.00495	CcSEcCtD
Repaglinide—Hepatic enzyme increased—Methotrexate—lymphatic system cancer	0.00236	0.00494	CcSEcCtD
Repaglinide—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00235	0.00492	CcSEcCtD
Repaglinide—Visual impairment—Carmustine—lymphatic system cancer	0.00233	0.00488	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00231	0.00485	CcSEcCtD
Repaglinide—Constipation—Fludarabine—lymphatic system cancer	0.00229	0.00481	CcSEcCtD
Repaglinide—Vasculitis—Methotrexate—lymphatic system cancer	0.00228	0.00478	CcSEcCtD
Repaglinide—Eye disorder—Carmustine—lymphatic system cancer	0.00226	0.00473	CcSEcCtD
Repaglinide—Rhinitis—Mitoxantrone—lymphatic system cancer	0.00225	0.00472	CcSEcCtD
Repaglinide—Hypersensitivity—Teniposide—lymphatic system cancer	0.00225	0.00471	CcSEcCtD
Repaglinide—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00225	0.00471	CcSEcCtD
Repaglinide—Pruritus—Teniposide—lymphatic system cancer	0.00216	0.00452	CcSEcCtD
Repaglinide—Arrhythmia—Carmustine—lymphatic system cancer	0.00216	0.00452	CcSEcCtD
Repaglinide—Leukopenia—Bleomycin—lymphatic system cancer	0.00216	0.00452	CcSEcCtD
Repaglinide—Cardiac disorder—Vincristine—lymphatic system cancer	0.00214	0.00449	CcSEcCtD
Repaglinide—Alopecia—Carmustine—lymphatic system cancer	0.00213	0.00447	CcSEcCtD
Repaglinide—Erythema—Carmustine—lymphatic system cancer	0.0021	0.00441	CcSEcCtD
Repaglinide—Malnutrition—Carmustine—lymphatic system cancer	0.0021	0.00441	CcSEcCtD
Repaglinide—Diarrhoea—Teniposide—lymphatic system cancer	0.00209	0.00438	CcSEcCtD
Repaglinide—Chest pain—Bleomycin—lymphatic system cancer	0.00205	0.0043	CcSEcCtD
Repaglinide—Alopecia—Vincristine—lymphatic system cancer	0.00204	0.00427	CcSEcCtD
Repaglinide—Back pain—Carmustine—lymphatic system cancer	0.00203	0.00426	CcSEcCtD
Repaglinide—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00201	0.0042	CcSEcCtD
Repaglinide—Alopecia—Mitoxantrone—lymphatic system cancer	0.00198	0.00416	CcSEcCtD
Repaglinide—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00198	0.00414	CcSEcCtD
Repaglinide—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00197	0.00412	CcSEcCtD
Repaglinide—Oedema—Bleomycin—lymphatic system cancer	0.00197	0.00412	CcSEcCtD
Repaglinide—Erythema—Mitoxantrone—lymphatic system cancer	0.00195	0.0041	CcSEcCtD
Repaglinide—Back pain—Vincristine—lymphatic system cancer	0.00194	0.00407	CcSEcCtD
Repaglinide—Vomiting—Teniposide—lymphatic system cancer	0.00194	0.00407	CcSEcCtD
Repaglinide—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.00192	0.00403	CcSEcCtD
Repaglinide—Rash—Teniposide—lymphatic system cancer	0.00192	0.00403	CcSEcCtD
Repaglinide—Dermatitis—Teniposide—lymphatic system cancer	0.00192	0.00403	CcSEcCtD
Repaglinide—Headache—Teniposide—lymphatic system cancer	0.00191	0.00401	CcSEcCtD
Repaglinide—Pruritus—Fludarabine—lymphatic system cancer	0.0019	0.00398	CcSEcCtD
Repaglinide—Back pain—Mitoxantrone—lymphatic system cancer	0.00189	0.00396	CcSEcCtD
Repaglinide—Leukopenia—Carmustine—lymphatic system cancer	0.00188	0.00395	CcSEcCtD
Repaglinide—Diarrhoea—Fludarabine—lymphatic system cancer	0.00183	0.00385	CcSEcCtD
Repaglinide—Hypertension—Carmustine—lymphatic system cancer	0.00182	0.00381	CcSEcCtD
Repaglinide—Nausea—Teniposide—lymphatic system cancer	0.00181	0.0038	CcSEcCtD
Repaglinide—Leukopenia—Vincristine—lymphatic system cancer	0.0018	0.00377	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00179	0.00375	CcSEcCtD
Repaglinide—Chest pain—Carmustine—lymphatic system cancer	0.00179	0.00375	CcSEcCtD
Repaglinide—Paraesthesia—Bleomycin—lymphatic system cancer	0.00177	0.0037	CcSEcCtD
Repaglinide—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00175	0.00367	CcSEcCtD
Repaglinide—Hypertension—Vincristine—lymphatic system cancer	0.00173	0.00363	CcSEcCtD
Repaglinide—Oedema—Carmustine—lymphatic system cancer	0.00172	0.0036	CcSEcCtD
Repaglinide—Visual disturbance—Methotrexate—lymphatic system cancer	0.00171	0.00358	CcSEcCtD
Repaglinide—Vomiting—Fludarabine—lymphatic system cancer	0.0017	0.00357	CcSEcCtD
Repaglinide—Rash—Fludarabine—lymphatic system cancer	0.00169	0.00354	CcSEcCtD
Repaglinide—Dermatitis—Fludarabine—lymphatic system cancer	0.00169	0.00354	CcSEcCtD
Repaglinide—Hypertension—Mitoxantrone—lymphatic system cancer	0.00169	0.00354	CcSEcCtD
Repaglinide—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00168	0.00352	CcSEcCtD
Repaglinide—Headache—Fludarabine—lymphatic system cancer	0.00168	0.00352	CcSEcCtD
Repaglinide—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.00167	0.0035	CcSEcCtD
Repaglinide—Chest pain—Mitoxantrone—lymphatic system cancer	0.00166	0.00349	CcSEcCtD
Repaglinide—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00166	0.00349	CcSEcCtD
Repaglinide—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00164	0.00343	CcSEcCtD
Repaglinide—Oedema—Vincristine—lymphatic system cancer	0.00164	0.00343	CcSEcCtD
Repaglinide—Thrombocytopenia—Vincristine—lymphatic system cancer	0.0016	0.00336	CcSEcCtD
Repaglinide—Oedema—Mitoxantrone—lymphatic system cancer	0.0016	0.00334	CcSEcCtD
Repaglinide—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.0016	0.00334	CcSEcCtD
Repaglinide—Nausea—Fludarabine—lymphatic system cancer	0.00159	0.00334	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00156	0.00328	CcSEcCtD
Repaglinide—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.00156	0.00327	CcSEcCtD
Repaglinide—Urticaria—Bleomycin—lymphatic system cancer	0.00156	0.00327	CcSEcCtD
Repaglinide—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00155	0.00325	CcSEcCtD
Repaglinide—Paraesthesia—Carmustine—lymphatic system cancer	0.00154	0.00323	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00149	0.00313	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00148	0.00311	CcSEcCtD
Repaglinide—Paraesthesia—Vincristine—lymphatic system cancer	0.00147	0.00308	CcSEcCtD
Repaglinide—Constipation—Carmustine—lymphatic system cancer	0.00147	0.00308	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00145	0.00305	CcSEcCtD
Repaglinide—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00145	0.00304	CcSEcCtD
Repaglinide—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00143	0.003	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00141	0.00296	CcSEcCtD
Repaglinide—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.0014	0.00294	CcSEcCtD
Repaglinide—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.0014	0.00294	CcSEcCtD
Repaglinide—Constipation—Vincristine—lymphatic system cancer	0.0014	0.00294	CcSEcCtD
Repaglinide—Pruritus—Bleomycin—lymphatic system cancer	0.00139	0.00292	CcSEcCtD
Repaglinide—Pancreatitis—Methotrexate—lymphatic system cancer	0.00137	0.00287	CcSEcCtD
Repaglinide—Constipation—Mitoxantrone—lymphatic system cancer	0.00136	0.00286	CcSEcCtD
Repaglinide—Abdominal pain—Carmustine—lymphatic system cancer	0.00136	0.00284	CcSEcCtD
Repaglinide—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00134	0.00281	CcSEcCtD
Repaglinide—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.0013	0.00273	CcSEcCtD
Repaglinide—Abdominal pain—Vincristine—lymphatic system cancer	0.0013	0.00271	CcSEcCtD
Repaglinide—Urticaria—Mitoxantrone—lymphatic system cancer	0.00127	0.00266	CcSEcCtD
Repaglinide—Hypersensitivity—Carmustine—lymphatic system cancer	0.00126	0.00265	CcSEcCtD
Repaglinide—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00126	0.00264	CcSEcCtD
Repaglinide—Vomiting—Bleomycin—lymphatic system cancer	0.00125	0.00262	CcSEcCtD
Repaglinide—Rash—Bleomycin—lymphatic system cancer	0.00124	0.0026	CcSEcCtD
Repaglinide—Dermatitis—Bleomycin—lymphatic system cancer	0.00124	0.0026	CcSEcCtD
Repaglinide—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.00124	0.00259	CcSEcCtD
Repaglinide—Hypersensitivity—Vincristine—lymphatic system cancer	0.00121	0.00253	CcSEcCtD
Repaglinide—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00118	0.00247	CcSEcCtD
Repaglinide—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00118	0.00246	CcSEcCtD
Repaglinide—Diarrhoea—Carmustine—lymphatic system cancer	0.00117	0.00246	CcSEcCtD
Repaglinide—Nausea—Bleomycin—lymphatic system cancer	0.00117	0.00245	CcSEcCtD
Repaglinide—Diarrhoea—Vincristine—lymphatic system cancer	0.00112	0.00235	CcSEcCtD
Repaglinide—Hepatitis—Methotrexate—lymphatic system cancer	0.00112	0.00235	CcSEcCtD
Repaglinide—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00109	0.00229	CcSEcCtD
Repaglinide—Vomiting—Carmustine—lymphatic system cancer	0.00109	0.00229	CcSEcCtD
Repaglinide—Rash—Carmustine—lymphatic system cancer	0.00108	0.00227	CcSEcCtD
Repaglinide—Dermatitis—Carmustine—lymphatic system cancer	0.00108	0.00227	CcSEcCtD
Repaglinide—Visual impairment—Methotrexate—lymphatic system cancer	0.00108	0.00226	CcSEcCtD
Repaglinide—Headache—Carmustine—lymphatic system cancer	0.00108	0.00225	CcSEcCtD
Repaglinide—Erythema multiforme—Methotrexate—lymphatic system cancer	0.00106	0.00222	CcSEcCtD
Repaglinide—Eye disorder—Methotrexate—lymphatic system cancer	0.00105	0.00219	CcSEcCtD
Repaglinide—Vomiting—Vincristine—lymphatic system cancer	0.00104	0.00218	CcSEcCtD
Repaglinide—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00104	0.00218	CcSEcCtD
Repaglinide—Rash—Vincristine—lymphatic system cancer	0.00103	0.00216	CcSEcCtD
Repaglinide—Dermatitis—Vincristine—lymphatic system cancer	0.00103	0.00216	CcSEcCtD
Repaglinide—Headache—Vincristine—lymphatic system cancer	0.00103	0.00215	CcSEcCtD
Repaglinide—Nausea—Carmustine—lymphatic system cancer	0.00102	0.00214	CcSEcCtD
Repaglinide—Vomiting—Mitoxantrone—lymphatic system cancer	0.00101	0.00213	CcSEcCtD
Repaglinide—Immune system disorder—Methotrexate—lymphatic system cancer	0.00101	0.00212	CcSEcCtD
Repaglinide—Rash—Mitoxantrone—lymphatic system cancer	0.00101	0.00211	CcSEcCtD
Repaglinide—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00101	0.00211	CcSEcCtD
Repaglinide—Headache—Mitoxantrone—lymphatic system cancer	0.000999	0.00209	CcSEcCtD
Repaglinide—Alopecia—Methotrexate—lymphatic system cancer	0.000989	0.00207	CcSEcCtD
Repaglinide—Erythema—Methotrexate—lymphatic system cancer	0.000974	0.00204	CcSEcCtD
Repaglinide—Malnutrition—Methotrexate—lymphatic system cancer	0.000974	0.00204	CcSEcCtD
Repaglinide—Nausea—Vincristine—lymphatic system cancer	0.000973	0.00204	CcSEcCtD
Repaglinide—Nausea—Mitoxantrone—lymphatic system cancer	0.000948	0.00199	CcSEcCtD
Repaglinide—Back pain—Methotrexate—lymphatic system cancer	0.000942	0.00197	CcSEcCtD
Repaglinide—Leukopenia—Methotrexate—lymphatic system cancer	0.000872	0.00183	CcSEcCtD
Repaglinide—Arthralgia—Methotrexate—lymphatic system cancer	0.000829	0.00174	CcSEcCtD
Repaglinide—Chest pain—Methotrexate—lymphatic system cancer	0.000829	0.00174	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000823	0.00173	CcSEcCtD
Repaglinide—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000795	0.00167	CcSEcCtD
Repaglinide—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.000778	0.00163	CcSEcCtD
Repaglinide—Skin disorder—Methotrexate—lymphatic system cancer	0.000772	0.00162	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000724	0.00152	CcSEcCtD
Repaglinide—Paraesthesia—Methotrexate—lymphatic system cancer	0.000714	0.0015	CcSEcCtD
Repaglinide—Dyspepsia—Methotrexate—lymphatic system cancer	0.0007	0.00147	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000686	0.00144	CcSEcCtD
Repaglinide—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.00065	0.00136	CcSEcCtD
Repaglinide—Urticaria—Methotrexate—lymphatic system cancer	0.000631	0.00132	CcSEcCtD
Repaglinide—Abdominal pain—Methotrexate—lymphatic system cancer	0.000628	0.00132	CcSEcCtD
Repaglinide—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000586	0.00123	CcSEcCtD
Repaglinide—Pruritus—Methotrexate—lymphatic system cancer	0.000562	0.00118	CcSEcCtD
Repaglinide—Diarrhoea—Methotrexate—lymphatic system cancer	0.000544	0.00114	CcSEcCtD
Repaglinide—Vomiting—Methotrexate—lymphatic system cancer	0.000505	0.00106	CcSEcCtD
Repaglinide—Rash—Methotrexate—lymphatic system cancer	0.000501	0.00105	CcSEcCtD
Repaglinide—Dermatitis—Methotrexate—lymphatic system cancer	0.000501	0.00105	CcSEcCtD
Repaglinide—Headache—Methotrexate—lymphatic system cancer	0.000498	0.00104	CcSEcCtD
Repaglinide—Nausea—Methotrexate—lymphatic system cancer	0.000472	0.00099	CcSEcCtD
